ALEC EBRAIM VAEZI Medical Practice in Pittsburgh, PA
License number
Pennsylvania MD436838
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
Pittsburgh, PA 15232
Professional information
Alec Vaezi, Worcester MA
Work:
Umass Memorial Medical Center - University Campus 55 Lake Ave N, Worcester, MA 01655UPMC Latterman Family Health Center 5200 Centre Ave, Pittsburgh, PA 15232Eye & Ear Institute 200 Lothrop St, Pittsburgh, PA 15213
Dr. Alec E Vaezi, Pittsburgh PA - MD (Doctor of Medicine)
Specialties:
Ear, Nose, and Throat
Address:
5200 Centre Ave STE 211, Pittsburgh 15232 (412) 621-0123 (Phone) UNIVERSITY OF MASSACHUSETTS MEMORIAL MEDICAL CENTER 55 Lake Ave N, Worcester 01655 (508) 334-3206 (Phone), (508) 856-4668 (Fax)
Certifications:
Otolaryngology, 2010
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
5200 Centre Ave STE 211, Pittsburgh 15232 UNIVERSITY OF MASSACHUSETTS MEMORIAL MEDICAL CENTER 55 Lake Ave N, Worcester 01655 Upmc Mercy 1400 Locust St, Pittsburgh 15219 UPMC Passavant - Cranberry 1 Saint Francis Way, Cranberry Twp 16066 Upmc Shadyside 5230 Center Ave, Pittsburgh 15232
Use Of Choline-Phosphate Cytidylyltransferase-Alpha (Cct-Alpha) As A Biomarker For Cancer Prognosis
US Patent:
2013020, Aug 8, 2013
Filed:
Feb 4, 2013
Appl. No.:
13/758780
Inventors:
University of Pittsburgh - Of the Commonwealth System of Higher Education - Pittsburgh PA, US Nikhil Ramchandra Bhagwat - Pittsburgh PA, US Alec E. Vaezi - Pittsburgh PA, US
International Classification:
G01N 33/68
US Classification:
424 946, 435 74, 435 613, 435 612, 506 9, 435 611
Abstract:
It has previously been demonstrated that positive 8F1 immunohistochemistry is an indicator of a poor cancer prognosis and poor response to chemotherapy. The 8F1 antibody was generated by immunization against ERCC1, a DNA repair protein, but recognizes a second, previously unidentified protein in cells and tissues. Disclosed herein is the finding that in addition to ERCC1, the 8F1 antibody recognizes the choline phosphate cytidylyltransferase-α (CCTα) protein. Thus, provided herein is a method of determining the prognosis of a patient with cancer by specifically detecting expression of CCTα in a sample obtained from the subject. Also provided is a method of predicting the response of a cancer patient to treatment with a genotoxic therapy by specifically detecting expression of CCTα in a sample obtained from the subject.